WO2006020755A3 - Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics - Google Patents

Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics Download PDF

Info

Publication number
WO2006020755A3
WO2006020755A3 PCT/US2005/028523 US2005028523W WO2006020755A3 WO 2006020755 A3 WO2006020755 A3 WO 2006020755A3 US 2005028523 W US2005028523 W US 2005028523W WO 2006020755 A3 WO2006020755 A3 WO 2006020755A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diabetes
mtor pathway
identifying inhibitors
diabetes therapeutics
Prior art date
Application number
PCT/US2005/028523
Other languages
French (fr)
Other versions
WO2006020755A2 (en
WO2006020755A9 (en
Inventor
Lewis C Cantley
Reuben J Shaw
Brendan D Manning
Original Assignee
Beth Israel Hospital
Lewis C Cantley
Reuben J Shaw
Brendan D Manning
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Lewis C Cantley, Reuben J Shaw, Brendan D Manning filed Critical Beth Israel Hospital
Publication of WO2006020755A2 publication Critical patent/WO2006020755A2/en
Publication of WO2006020755A9 publication Critical patent/WO2006020755A9/en
Publication of WO2006020755A3 publication Critical patent/WO2006020755A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Abstract

The invention relates to inhibition of mTOR, p70S6K1 or Rheb kinase activity for treating disorders including diabetes. The invention also relates to screening for agents that inhibit the activities of mTOR, p70S6K1 or Rheb proteins, which are useful in the treatment of diabetes, as well as preparing compounds for treatment of diabetes.
PCT/US2005/028523 2004-08-10 2005-08-10 Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics WO2006020755A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60019304P 2004-08-10 2004-08-10
US60/600,193 2004-08-10

Publications (3)

Publication Number Publication Date
WO2006020755A2 WO2006020755A2 (en) 2006-02-23
WO2006020755A9 WO2006020755A9 (en) 2006-03-23
WO2006020755A3 true WO2006020755A3 (en) 2006-07-06

Family

ID=35500665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/028523 WO2006020755A2 (en) 2004-08-10 2005-08-10 Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics

Country Status (1)

Country Link
WO (1) WO2006020755A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
JP5528708B2 (en) 2006-02-09 2014-06-25 参天製薬株式会社 Stable formulations and methods for preparing and using them
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP2014520119A (en) * 2011-06-17 2014-08-21 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods for increasing insulin sensitivity and methods for treating diabetes
BR112019027402A2 (en) 2017-06-22 2020-07-07 Celgene Corporation treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039736A1 (en) * 2000-06-05 2002-04-04 Byrne Michael C. Compositions, kits, and methods for identification and modulation of type I diabetes
WO2002079786A2 (en) * 2001-03-30 2002-10-10 Biostratum Ab Method for identifying drugs for the treatment of type ii diabetes
US20030170287A1 (en) * 2002-01-10 2003-09-11 Prescott Margaret Forney Drug delivery systems for the prevention and treatment of vascular diseases
WO2003104481A2 (en) * 2002-06-08 2003-12-18 University Of Dundee Methods
WO2004035815A1 (en) * 2002-10-18 2004-04-29 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation of s6 kinase activity for the treatment of obestiy
US20050009112A1 (en) * 2003-03-07 2005-01-13 Fred Hutchinson Cancer Research Center, Office Of Technology Transfer Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth
WO2005019829A1 (en) * 2003-08-22 2005-03-03 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Inhibition of s6 kinase activity for the treatment of insulin resistance

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039736A1 (en) * 2000-06-05 2002-04-04 Byrne Michael C. Compositions, kits, and methods for identification and modulation of type I diabetes
WO2002079786A2 (en) * 2001-03-30 2002-10-10 Biostratum Ab Method for identifying drugs for the treatment of type ii diabetes
US20030170287A1 (en) * 2002-01-10 2003-09-11 Prescott Margaret Forney Drug delivery systems for the prevention and treatment of vascular diseases
WO2003104481A2 (en) * 2002-06-08 2003-12-18 University Of Dundee Methods
WO2004035815A1 (en) * 2002-10-18 2004-04-29 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation of s6 kinase activity for the treatment of obestiy
US20050009112A1 (en) * 2003-03-07 2005-01-13 Fred Hutchinson Cancer Research Center, Office Of Technology Transfer Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth
WO2005019829A1 (en) * 2003-08-22 2005-03-03 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Inhibition of s6 kinase activity for the treatment of insulin resistance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUAL P ET AL: "MAP kinases and mTOR mediate insulin-induced phosphorylation of Insulin Receptor Substrate-1 on serine residues 307, 612 and 632.", DIABETOLOGIA, vol. 46, no. 11, November 2003 (2003-11-01), pages 1532 - 1542, XP002361773, ISSN: 0012-186X *
MANNING B D ET AL: "Rheb fills a GAP between TSC and TOR", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, HAYWARDS, GB, vol. 28, no. 11, November 2003 (2003-11-01), pages 573 - 576, XP004471234, ISSN: 0968-0004 *

Also Published As

Publication number Publication date
WO2006020755A2 (en) 2006-02-23
WO2006020755A9 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
NO20082476L (en) Bicyclic compounds with kinase inhibitory activity
ATE482213T1 (en) PYRAZOLOÄ1,5-AÜPYRIMIDINES SUITABLE AS INHIBITORS OF PROTEIN KINASES
WO2007079164A3 (en) Protein kinase inhibitors
ATE493401T1 (en) DIAMINOTRIAZOLE COMPOUNDS SUITABLE AS PROTEIN KINASE INHIBITORS
TW200633980A (en) Pyridones useful as inhibitors of kinases
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2005012241A3 (en) p-38 KINASE INHIBITORS
NO20083918L (en) Dihydridiazepines useful as inhibitors of protein kinases
EA200970403A1 (en) BICYCLIC TRIAZOLES AS PROTEINKINASE MODULATORS
EA200901486A1 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
WO2007123892A3 (en) Raf inhibitors and their uses
DE602007007985D1 (en) AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINO-PRIMIDINES
WO2007149427A3 (en) Tyrosine kinase inhibitors
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
ATE450530T1 (en) COMPOSITIONS FOR USE AS PROTEIN KINASE INHIBITORS
WO2005076854A3 (en) Pyrimidinone compounds useful as kinase inhibitors
WO2006020755A3 (en) Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
WO2009038385A3 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
EA200901484A1 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
WO2006078574A3 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 1/1, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase